Related Experiment Videos
Orally active, nonpeptide oxytocin antagonists.
B E Evans1, J L Leighton, K E Rittle
1Department of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486.
Journal of Medicinal Chemistry
|October 16, 1992
Summary
Researchers developed novel nonpeptide oxytocin (OT) antagonists, including L-366,509. These compounds show potential for treating preterm labor and offer new nonpeptide ligands for peptide receptors.
Area of Science:
- Pharmacology
- Endocrinology
- Medicinal Chemistry
Background:
- Oxytocin (OT) is a crucial neurohypophyseal hormone involved in labor and social bonding.
- Existing OT antagonists are primarily peptide-based, limiting their therapeutic applications.
- Development of nonpeptide antagonists is essential for novel pharmacological interventions.
Purpose of the Study:
- To describe the first nonpeptide antagonists of oxytocin (OT).
- To introduce novel spiroindenepiperidine derivatives as potent OT antagonists.
- To evaluate the therapeutic potential of these compounds in conditions like preterm labor.
Main Methods:
- Synthesis and characterization of novel spiroindenepiperidine compounds.
- In vitro and in vivo evaluation of oxytocin receptor antagonist activity.
- Assessment of pharmacokinetic properties, including oral bioavailability and duration of action.
Main Results:
- Successful development of nonpeptide oxytocin antagonists based on the spiroindenepiperidine scaffold.
- L-366,509 demonstrated oral bioavailability and sustained in vivo activity.
- These compounds represent a new class of nonpeptide ligands for peptide receptors.
Conclusions:
- The novel nonpeptide oxytocin antagonists are promising therapeutic agents.
- L-366,509 is a viable candidate for treating preterm labor.
- These findings expand the landscape of nonpeptide ligands for peptide receptors.